Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active ...

Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in ...

“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer. Detecting the condition can be a challenge, because those living ...

Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.